The UK Inflammatory Bowel Disease Bioresource: Progressing from Genetics to Function and Clinical Translation in Crohn's Disease & Ulcerative Colitis

Lead Research Organisation: University of Cambridge
Department Name: Medicine

Abstract

We are proposing to develop a centralised national recallable bioresource of 25,000 patients with Crohn's disease or ulcerative colitis (collectively inflammatory bowel disease) to support globally competitive scientific and clinical IBD research.

The IBD Bioresource would have the following key features:
1. DNA and serum + clinical and genetic data from 25,000 IBD patients recruited UK-wide - all stored in a central NIHR funded biorepository with technical input from UK Biobank
2. 1000 newly diagnosed IBD patients. Detailed samples unconfounded by treatment or surgery, plus follow-up samples (including stool) + clinical data
3. The first recallable IBD bioresource - allowing patients stratified by clinical subtype or carriage of specific IBD genetic risk variants to be recruited for stratified 'stage 2' scientific studies or clinical trials (each stage 2 study would require separate funding and new consent for each subject).

IBD affects 4 per 1000 Europeans, with peak onset in young adults. Despite steroids, immunosuppression and antibody therapies ~50% of patients require major surgery +/- colostomy for treatment failure or disease complications. Direct UK healthcare costs exceed £1billion/yr. Given major adverse impacts on health, education, relationships and jobs there is a pressing need to understand the causes of IBD and develop better treatments.

Since 2007 our group (the UK IBD Genetics Consortium) has, through national cohort building, international collaboration and use of leading technologies, made huge progress in understanding the genetic basis of IBD. In identifying >160 distinct genetic risk factors we have found evidence both of genetic strata within IBD and also of overlap between IBD and many other autoimmune diseases. The next steps, to fully capitalise on recent genetic advances, require functional analysis of the associated variants, to understand how they disturb cell function to cause IBD; and translation of this knowledge for clinical bnefit. These key steps sit at the heart of stratified medicine - and both critically depend on access to a large Bioresource of patients of known or ascertainable genotype such as we are proposing, to obtain fresh samples for analysis or to recruit patients to stratified clinical trials.

'Recall-ability' is a key novel feature - transforming our existing 'passive' collection of 14,000 DNA samples into a new interactive resource of 25,000 patients fully engaged and recallable for stratified studies led by any UK investigator from medicine, science or industry. The inception cohort will allow study of biomarkers, microbial triggers and epigenetics unconfounded by drug effects. Further, many non-IBD investigators, for example from psoriasis, arthritis and colon cancer, have expressed support and interest in using the Bioresource where genetic risk variants are shared with their 'own' disease and / or therapies overlap with IBD - to interrogate shared mechanisms of disease and drug non-response.

Here we are requesting a 5 year partnership grant in which the MRC supports 4 key IBD Bioresource personnel, sharing costs related to patient recruitment and sample gathering with the (NIHR funded) Clinical Research Network (CRN) whose involvement would be mandated by the MRC funding; while Cambridge Biomedical Research Centre (BRC) have agreed if this application is successful to fund all costs related to centralised sample processing, quality control and storage, together with IT support plus one IBD data manager.

Given its scale and ambition we believe this proposal represents excellent value for money. The IBD Bioresource would provide a key platform for the scientific and clinical exploitation of recent dramatic advances in IBD genetics, would foster cross-disease collaboration and substantially facilitate interaction with industry. In so-doing it would underpin globally competitive IBD and inflammation research in the UK for the next 10 years.

Technical Summary

Our main objective is to establish a centralised national Inflammatory Bowel Disease (IBD) Bioresource of 25,000 patients, from which subjects meeting inclusion criteria for approved downstream functional and clinical studies can be identified and recalled.

Subjects would be recruited from our existing network of UK IBD Genetics Consortium (UKIBDGC) collaborating hospitals. The study coordinators will train CRN (clinical research network) nurses in each site to organise recruitment, consent, sample and data collection. Such CRN nurses are paid by the NIHR: their contribution to this study would be mandated if it is funded by the MRC.

All IBD samples and data will be submitted to the NIHR BRC-MRC BioRepository team at Addenbrooke's, Cambridge. They have substantial expertise in high-throughput biological sample management, using LIMS tracking with automated storage and retrieval. Processing of all IBD samples will be undertaken by BioRepository personnel using established SOP's. DNA and serum will be extracted and quality checked using automated systems and deposited in fully monitored low temperature storage.

Dr Tim Peakman, Executive Director of UK Biobank, will provide strategic guidance on biobanking issues. Once UK Biobank BioRepository South is complete the intention is to move the IBD Bioresource to this new facility.

An IBD Bioresource management committee co-chaired by PI Parkes will, with the study coordinators, oversee recruitment and liaison with clinical centres. Proposals to use the IBD Bioresource will be reviewed by the NIHR BioResource scientific advisory board, including UKIBDGC representatives. Recall of patients for approved projects will be handled through the existing Cambridge NIHR BioResource mechanism.

Data generated on IBD Bioresource subjects (existing genotyping and sequencing data generated from our UKIBDGC studies) will be held on the central NIHR BioResource database and accessible to collaborating researchers.

Planned Impact

A national inflammatory bowel disease (IBD) Bioresource that capitalises on recent genetics advances and on existing UK-wide recruitment pipelines would be transformative for UK IBD research. For the first time it would bring together large, motivated and precisely characterised IBD patient cohorts with UK investigators from medicine, science or industry. By providing a platform for downstream studies, it would directly aid translation of new genetics knowledge to improved IBD treatment - as well as fostering collaborations across several disease areas and facilitating interactions with industry.

Beneficiaries
1. Patients with IBD, by galvanising research, improving treatments and driving towards a cure - so improving their confidence in and enthusiasm for research, and ultimately their health, wellbeing and economic productivity.

2. Individuals at risk of IBD, helped by biomarkers of risk prediction and the development of preventative strategies

3. Academics in IBD investigating
a.pharmacogenetics + low-frequency/rare genetic variants
b.epigenetics
c.biomarkers of prognosis
d.functional / immunological impact of risk variants
e.microbial triggers of IBD flares

4. Funding agencies (NIHR, MRC, WT) - who can access an engaged patient population to ascertain their research priorities

5. Academics outside IBD - from diseases where genetics, mechanistic pathways and therapies are shared with IBD. The cross-cutting utility is a key feature: investigators from rheumatoid arthritis, multiple sclerosis, ankylosing spondylitis, psoriasis, TB and colorectal cancer have already expressed their wish to use the IBD Bioresource.

6. Industry - both existing (MSD, Novartis and GSK) and new partners from biotech and pharmaceutical industries. Collaborations would encompass all stages from drug development to clinical trials / stratified and experimental medicine.

7. The NIHR Bioresource programme: as Dr Bradley indicates in his Project Partner letter - 'The high level vision of the NIHR BioResource is to promote recruitment of well genotyped and phenotyped patients .. in collaboration with the Clinical Research Network, and an initial focus is immunological and inflammatory disease'

8. Crohn's and Colitis UK - the patients' charity who keenly support this proposal for the sense of purpose, progress and optimism it will bring to the 150,000+ UK sufferers of IBD who would have the opportunity to participate in research wherever they live in the UK.

9. Developers of IBD health policy who will benefit from advances in biomarkers and methods of IBD stratification to improve targeting of high cost therapies.

Inherent in the proposal is direct patient engagement in research - for the first time joining together a large IBD patient cohort with investigators. 25,000 patients with IBD (representing ~15% of the UK total) would be informed of research studies for which their clinical or genetic profiles matched inclusion criteria, and where appropriate would be encouraged to participate.

Patient involvement will include a mechanism to survey views for example regarding IBD research priorities and relevant health policy such as NICE guidance - so allowing patients to directly influence these.

Such patient interaction is strongly supported by the NIHR and by the national patient support group charity Crohn's and Colitis UK.

Patients and users will be engaged through a variety of media including a website, social networking, lectures and lay / academic publications. Success will be gauged by numbers of patients recruited and outputs in terms of projects, grants and papers resulting; collaborations established; and new therapies tested through the IBD Bioresource.

Of note, there are no other recallable IBD Bioresources elsewhere. This emphasises the opportunity to provide a unique platform to support globally competitive IBD research over the next 10 years.

Publications

10 25 50

 
Title IBD Bioresource database 
Description We have built a new database using Redcap to capture clinical phenotype data on IBD patients nationwide. The server is hosted on the NHS N3 network at Cambridge University Hospital 
Type Of Material Database/Collection of data 
Year Produced 2016 
Provided To Others? Yes  
Impact This database will support our IBD genetic and pharmacogenetic work 
 
Description Clinical partners 
Organisation Imperial College London
Country United Kingdom 
Sector Academic/University 
PI Contribution Updated March 2018 - The above and 80+ other hospital around the UK are currently being set up to recruit to the UK IBD Bioresource. At the time of reporting we have 59 hospital sites open and recruiting, with another 24 due to open in the next 6 months. We currently have ~9,500 patients within the IBD BioResource.
Collaborator Contribution They will recruit patients with Crohn's disease and ulcerative colitis
Impact In set-up phase for the majority of the hospital, for those who are open, this involves recruiting patients into the study
Start Year 2016
 
Description Clinical partners 
Organisation Newcastle upon Tyne Hospitals NHS Foundation Trust
Country United Kingdom 
Sector Public 
PI Contribution Updated March 2018 - The above and 80+ other hospital around the UK are currently being set up to recruit to the UK IBD Bioresource. At the time of reporting we have 59 hospital sites open and recruiting, with another 24 due to open in the next 6 months. We currently have ~9,500 patients within the IBD BioResource.
Collaborator Contribution They will recruit patients with Crohn's disease and ulcerative colitis
Impact In set-up phase for the majority of the hospital, for those who are open, this involves recruiting patients into the study
Start Year 2016
 
Description Clinical partners 
Organisation Royal Devon and Exeter Hospital
Country United Kingdom 
Sector Academic/University 
PI Contribution Updated March 2018 - The above and 80+ other hospital around the UK are currently being set up to recruit to the UK IBD Bioresource. At the time of reporting we have 59 hospital sites open and recruiting, with another 24 due to open in the next 6 months. We currently have ~9,500 patients within the IBD BioResource.
Collaborator Contribution They will recruit patients with Crohn's disease and ulcerative colitis
Impact In set-up phase for the majority of the hospital, for those who are open, this involves recruiting patients into the study
Start Year 2016
 
Description Clinical partners 
Organisation University of Edinburgh
Country United Kingdom 
Sector Academic/University 
PI Contribution Updated March 2018 - The above and 80+ other hospital around the UK are currently being set up to recruit to the UK IBD Bioresource. At the time of reporting we have 59 hospital sites open and recruiting, with another 24 due to open in the next 6 months. We currently have ~9,500 patients within the IBD BioResource.
Collaborator Contribution They will recruit patients with Crohn's disease and ulcerative colitis
Impact In set-up phase for the majority of the hospital, for those who are open, this involves recruiting patients into the study
Start Year 2016
 
Description Clinical partners 
Organisation University of Oxford
Country United Kingdom 
Sector Academic/University 
PI Contribution Updated March 2018 - The above and 80+ other hospital around the UK are currently being set up to recruit to the UK IBD Bioresource. At the time of reporting we have 59 hospital sites open and recruiting, with another 24 due to open in the next 6 months. We currently have ~9,500 patients within the IBD BioResource.
Collaborator Contribution They will recruit patients with Crohn's disease and ulcerative colitis
Impact In set-up phase for the majority of the hospital, for those who are open, this involves recruiting patients into the study
Start Year 2016
 
Description Funding Partners 
Organisation Crohn's and Colitis UK
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution I have raised partnership funding from multiple different sources to support the IBD Bioresource
Collaborator Contribution They are providing financial support for employing staff and support with sample processing and patient recall (through the NIHR Bioresource)
Impact The IBD Bioresource was launched in Jan 2016. There have been no research outputs yet - but many potential users have been in touch
Start Year 2015
 
Description Funding Partners 
Organisation National Institute for Health Research
Department NIHR Cambridge Biomedical Research Centre
Country United Kingdom 
Sector Public 
PI Contribution I have raised partnership funding from multiple different sources to support the IBD Bioresource
Collaborator Contribution They are providing financial support for employing staff and support with sample processing and patient recall (through the NIHR Bioresource)
Impact The IBD Bioresource was launched in Jan 2016. There have been no research outputs yet - but many potential users have been in touch
Start Year 2015
 
Description Funding Partners 
Organisation The Wellcome Trust Sanger Institute
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution I have raised partnership funding from multiple different sources to support the IBD Bioresource
Collaborator Contribution They are providing financial support for employing staff and support with sample processing and patient recall (through the NIHR Bioresource)
Impact The IBD Bioresource was launched in Jan 2016. There have been no research outputs yet - but many potential users have been in touch
Start Year 2015
 
Description Genomics partners 
Organisation The Wellcome Trust Sanger Institute
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution We will supply DNA on 25000 patients with IBD
Collaborator Contribution They will undertake whole genome sequencing on 25000 patients with IBD, and undertake the analysis
Impact There have been multiple publications over many years from this long established collaboration • David Ellinghaus, Luke Jostins, Sarah L Spain, Adrian Cortes. Tom H Karlsen, Jeffrey C Barrett, Miles Parkes, Matthew A Brown, Andre Franke. Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci. Nat Genet. 2016 In press • Liu JZ, van Sommeren S, Huang H, Ng SC, Alberts R, Takahashi A, Ripke S, Lee JC, Jostins L, Shah T, Abedian S, Cheon JH, Cho J, Daryani NE, Franke L, Fuyuno Y, Hart A, Juyal RC, Juyal G, Kim WH, Morris AP, Poustchi H, Newman WG, Midha V, Orchard TR, Vahedi H, Sood A, Sung JJ, Malekzadeh R, Westra HJ, Yamazaki K, Yang SK; International Multiple Sclerosis Genetics Consortium; International IBD Genetics Consortium, Barrett JC, Franke A, Alizadeh BZ, Parkes M, B K T, Daly MJ, Kubo M, Anderson CA, Weersma RK. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat Genet. 2015 Sep;47(9):979-86. • Prescott NJ, Lehne B, Stone K, Lee JC, Taylor K, Knight J, Papouli E, Mirza MM, Simpson MA, Spain SL, Lu G, Fraternali F, Bumpstead SJ, Gray E, Amar A, Bye H, Green P, Chung-Faye G, Hayee B, Pollok R, Satsangi J, Parkes M, Barrett JC, Mansfield JC, Sanderson J, Lewis CM, Weale ME, Schlitt T, Mathew CG; UK IBD Genetics Consortium. Pooled sequencing of 531 genes in inflammatory bowel disease identifies an associated rare variant in BTNL2 and implicates other immune related genes. PLoS Genet. 2015 Feb 11;11(2):e1004955 • Heap GA, Weedon MN, Bewshea CM, Singh A, Chen M, Satchwell JB, Vivian JP, So K, Dubois PC, Andrews JM, Annese V, Bampton P, Barnardo M, Bell S, Cole A, Connor SJ, Creed T, Cummings FR, D'Amato M, Daneshmend TK, Fedorak RN, Florin TH, Gaya DR, Greig E, Halfvarson J, Hart A, Irving PM, Jones G, Karban A, Lawrance IC, Lee JC, Lees C, Lev-Tzion R, Lindsay JO, Mansfield J, Mawdsley J, Mazhar Z, Parkes M, Parnell K, Orchard TR, Radford-Smith G, Russell RK, Reffitt D, Satsangi J, Silverberg MS, Sturniolo GC, Tremelling M, Tsianos EV, van Heel DA, Walsh A, Watermeyer G, Weersma RK, Zeissig S, Rossjohn J, Holden AL; International Serious Adverse Events Consortium; IBD Pharmacogenetics Study Group, Ahmad T. HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. Nat Genet. 2014 Oct;46(10):1131-4 • Parkes M, Cortes A, van Heel D, Brown M. Analysis Article: Genetic insights into common pathways and complex relationships among immune mediated diseases. Nature Reviews Genetics 2013. Sep;14(9):661-73 • Ellinghaus D, Zhang H, Zeissig S, Lipinski S, Till A, .., Annese V, Halfvarson J, D'Amato M, Daly MJ, Nothnagel M, Karlsen TH, Subramani S, Rosenstiel P, Schreiber S, Parkes M*, Franke A*. Association Between Variants of PRDM1 and NDP52 and Crohn's Disease, Based on Exome Sequencing and Functional Studies. Gastroenterology. 2013 Apr 25. [Epub ahead of print] • Wellcome Trust Case Control Consortium. Bayesian refinement of association signals for 14 loci in 3 common diseases. Nat Genet. 2012 Dec;44(12):1294-301. • Jostins L*, Ripke S* .. Daly MJ, Franke A, Parkes M, Vermeire S, Barrett JC, Cho JH. Host-microbe interactions shape genetic risk for inflammatory bowel disease. Nature, 2012 Nov 491(7422):119-24. • Franke A, McGovern DP Hakonarson H, Daly MJ, Parkes M. Genome-Wide Meta-Analysis Increases to 71 the Number of Confirmed Crohn's Disease Susceptibility Loci. Nature Genetics. 2010;42(12):1118-25. • Anderson CA, Daly MJ, Barrett JC, Parkes M, Annese V, Hakonarson H, Radford-Smith G, Duerr RH, Vermeire S, Weersma RK, Rioux JD. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet. 2011 Mar;43(3):246-52. • Wellcome Trust Case Control Consortium. Craddock N, Hurles ME, , Parkes M, Rahman N, Todd JA, Samani NJ, Donnelly P. Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature. 2010 Apr 1;464(7289):713-20. • The UK IBD Genetics Consortium and WTCCC2 Genome-wide association study of ulcerative colitis identifies three susceptibility loci, including HNF4A. Nature Genetics 2009 Dec;41(12):1330-4. • Anderson CA Mathew CG, Satsangi J, Parkes M. Investigation of Crohn's disease risk loci in Ulcerative Colitis further defines their molecular relationship. Gastroenterology 2009 Feb;136(2):523-9. • Barrett JC, , Parkes M, Georges M, Daly MJ. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nature Genetics. 2008 Aug;40(8):955-62. • Fisher SA, , Parkes M, Satsangi J. Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohn's disease. Nature Genetics 2008 Jun;40(6):710-2. • Parkes M, Barrett JC, Prescott NJ, . Sanderson J, Jewell DP, Satsangi J, Mansfield JC; Wellcome Trust Case Control Consortium, Cardon L, Mathew CG. Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility. Nature Genetics. 2007 Jul;39(7):830-2 • Wellcome Trust Case Control Consortium [Primary Investigators: Bentley D, Parkes M, Pembrey M, Rahman N, Samani NJ, Stratton MR, Todd JA, Worthington J] Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007; 447, 661-678
Start Year 2008
 
Description Microbiota partner 
Organisation University of Aberdeen
Country United Kingdom 
Sector Academic/University 
PI Contribution Providing stool and biopsy samples for microbiota analysis
Collaborator Contribution Sample processing and storage
Impact Publication: Kennedy NA, Lamb CA, Berry SH, Walker AW, Mansfield J, Parkes M..... Lees CW, (2018). The Impact of NOD2 Variants on Fecal Microbiota in Crohn's Disease and Controls Without Gastrointestinal Disease.. Inflammatory bowel diseases, 24 (3), pp. 583-592
Start Year 2016
 
Description BSG Conference 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Research coordinators to attend to update the professional community on the progress of IBD BioResource
Year(s) Of Engagement Activity 2016,2017,2018,2019
 
Description BSG Investigator meeting 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact To update the Gastroenterology community about the work of IBD BioResource and encourage the use of the IBD BioResource panel for downstream research studies.
Year(s) Of Engagement Activity 2018
 
Description British Society of Gastroenterology 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Research Co-ordinators attended the BSG conference with a poster and information, aimed at raising awareness of the study to professionals and clinicians
Year(s) Of Engagement Activity 2016
 
Description Dr Falk Pharma Symposium 214: Inflammatory Bowel Disease: From Pathophysiology to Personalized Medicine 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact To update the Gastroenterology community about the work of IBD BioResource and encourage the use of the IBD BioResource panel for downstream research studies.
Year(s) Of Engagement Activity 2019
 
Description IBD BioResource Facebook account 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact To engage with the general public and the patient community. To promote and update about the IBD BioResource progress.
Year(s) Of Engagement Activity 2018
URL https://www.facebook.com/IBDBioresource/
 
Description IBD BioResource Twitter account 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact To promote and update the IBD BioResource progress. To engage with the wider community.
Year(s) Of Engagement Activity 2018
URL https://twitter.com/IBD_BioResource
 
Description IBD BioResource network created on LinkedIn 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact To update and promote the progress of the IBD BioResource. To engage further with members of its network.
Year(s) Of Engagement Activity 2018
URL https://www.linkedin.com/in/ibd-bioresource-b011a0157/
 
Description IBD BioResource website 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact To promote the IBD BioResource and update on is progress.
Year(s) Of Engagement Activity 2016,2017,2018,2019
URL http://www.ibdbioresource.nihr.ac.uk/
 
Description IBD PATIENT INVOLVEMENT IN RESEARCH DAY 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Patients, carers and/or patient groups
Results and Impact Research coordinators to attend to raise awareness of the IBD BioResource platform within the patient community
Year(s) Of Engagement Activity 2018
 
Description Immunogenomics Conference 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Research Co-ordinators attended Immunogenomics conference to raise awareness of the resource that scientists/clinicians/industry could access
Year(s) Of Engagement Activity 2017
 
Description Immunogenomics of Disease 2019 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact To let the Genomics community know about the work of IBD BioResource and encourage the use of the IBD BioResource panel for downstream research studies.
Year(s) Of Engagement Activity 2019
 
Description Medicine Research Day 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Postgraduate students
Results and Impact To update the department of Medicine about the work of IBD BioResource and encourage the use of the IBD BioResource panel for downstream research studies.
Year(s) Of Engagement Activity 2018
 
Description Midland Gastroenterology Society summer Conference 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Research Co-ordinators to attend meeting to raise awareness of the resource that scientists/clinicians/industry could access
Year(s) Of Engagement Activity 2018
 
Description Milner Therapeutics Symposium 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Industry/Business
Results and Impact To showcase the work of IBD BioResource and encourage Industries access to the IBD BioResource panel.
Year(s) Of Engagement Activity 2018
 
Description Mucosal Immunology Course and Symposium 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact To let the Immunology community know about the work of IBD BioResource and encourage the use of the IBD BioResource panel for downstream research studies.
Year(s) Of Engagement Activity 2018
 
Description NIHR Newsletter 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact To provide an update on who is part of the IBD BioResource and what it does.
Year(s) Of Engagement Activity 2018
 
Description Patients Newsletter 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Patients, carers and/or patient groups
Results and Impact To update the current IBD BioResource registered patients on the progress of the work being carried out
Year(s) Of Engagement Activity 2019
 
Description Press Release 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Media (as a channel to the public)
Results and Impact Press release to let the wider audience know about a very important milestone reached by the IBD BioResource and its network: 10,000 patients recruited
Year(s) Of Engagement Activity 2018
 
Description Press Release 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Media (as a channel to the public)
Results and Impact Press release to let the wider audience know about a very important milestone reached by the IBD BioResource and its network: 10,000 patients recruited
Year(s) Of Engagement Activity 2018
 
Description Public Engagement Event 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Patients, carers and/or patient groups
Results and Impact Research Co-ordinators attend local hospital open day, with a publicity stand. to raise awareness of the study.
Year(s) Of Engagement Activity 2016
 
Description Public engagement at NIHR Bioresource event 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact The IBD Bioresource coordinator team had a stand and presented information to interested members of the public
Year(s) Of Engagement Activity 2016
 
Description Site Newsletter 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact To update the current IBD BioResource registered sites on the progress of the work being carried out
Year(s) Of Engagement Activity 2018,2019
 
Description Wessex Mucosal Immunology Meeting 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact To let the Immunology community know about the work of IBD BioResource and encourage the use of the IBD BioResource panel for downstream research studies.
Year(s) Of Engagement Activity 2018
 
Description West Midlands Immunology Group symposium 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Research Co-ordinators to attend meeting to raise awareness of the resource that scientists/clinicians/industry could access.
Year(s) Of Engagement Activity 2018